IMMUNITYBIO, INC. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IMMUNITYBIO, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2021-06-30 was $0.00.
- IMMUNITYBIO, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2021-03-31 was $0.00.
- IMMUNITYBIO, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2020-12-31 was $0.00.
- IMMUNITYBIO, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2020-09-30 was $0.00.
- IMMUNITYBIO, INC. stock issued during period, value, restricted stock award, gross for fiscal 2018 was $0.00.
- IMMUNITYBIO, INC. stock issued during period, value, restricted stock award, gross for fiscal 2017 was $0.00.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 4 quarters · filed 2021-08-12 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-14 | $0.00 derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-12-31 | $0.00 derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | $0.00 8-K/A · filed 2021-04-22 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-14 | $0.00 derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $0.00 derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | $0.00 8-K/A · filed 2021-04-22 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | $0.00 derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 | $0.00 derived: sum of 4 quarters · filed 2021-03-04 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $0.00 10-K · filed 2021-03-04 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | |
| 2017-12-31 | $0.00 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |